Dawnrays Pharmaceutical (Holdings) Limited (2348.HK)

HKD 1.2

(-0.83%)

Market Cap (In HKD)

1.8 Billion

Revenue (In HKD)

1.15 Billion

Net Income (In HKD)

326 Million

Avg. Volume

123.12 Thousand

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0-1.4
PE
-
EPS
-
Beta Value
0.678
ISIN
KYG2687M1006
CUSIP
G2687M100
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Ms. Liwei Yu
Employee Count
-
Website
https://www.dawnrays.com
Ipo Date
2003-07-11
Details
Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, and oral antibiotics. It also provides and system specific medicines comprising cardiovascular systems; anti-allergic, anti-HBV, and digestive systems; urinary systems; and anti-pyretic analgesic, respiratory, and endocrine system drugs in the form of tablets, capsules, and granules. The company was founded in 1995 and is headquartered in Wan Chai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited is a subsidiary of Fortune United Group Limited.